OnkosXcel Therapeutics has submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock following its conversion into a corporation.
OnkosXcel is a subsidiary of BioXcel Therapeutics.
The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.